Acelyrin shares are trading lower after the company's Part B of a Phase 2b/3 trial of izokibep for Hidradenitis Suppurativa failed to meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Acelyrin's shares are trading down following the failure of Part B of a Phase 2b/3 trial of izokibep for Hidradenitis Suppurativa to meet its primary endpoint.
September 12, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acelyrin's stock is trading down due to the failure of a key clinical trial.
The failure of a key clinical trial often leads to a decrease in a company's stock price as it indicates a setback in the company's product development and potential future revenue. This is the case with Acelyrin, which saw its stock price drop following the failure of Part B of a Phase 2b/3 trial of izokibep.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100